SynOx Therapeutics secures €37M from HealthCap and Medicxi in co-lead, joined by Forbion and Gimv

SynOx Therapeutics Ltd, a Dublin, Ireland-based clinical stage biopharmaceutical company, announced the closing of a €37 million ($44M) Series A financing round.

The money was raised from investors co-led by HealthCap and Medicxi and joined by investors Forbion and Gimv. 

SynOx, a spin out of Celleron Therapeutics Ltd led by CEO Nick La Thangue, secured exclusive world-wide rights for the clinical development, manufacturing and commercialization of emactuzumab under a licence agreement with Roche.The financing will enable SynOx to continue the development of emactuzumab, for the treatment of diffuse tenosynovial giant cell tumours, also known as pigmented villonodular synovitis, and other indications.